

## Special Issue

# Advances in Glycoconjugate Vaccines and Nanovaccines

### Message from the Guest Editors

Glycoconjugate vaccines, obtained by linking carbohydrates to protein carriers, have had a critical role in fighting infectious diseases and, despite the new mRNA-based technologies, still are a valuable strategy to develop anti-infection and anti-cancer vaccines, from preclinical to clinical stages. Indeed, they are particularly effective in targeting carbohydrates, which are one of the most important classes of surface antigens, and which can also be used as adjuvants to promote immunostimulant effects as well as for promoting antigen or nucleic acid delivery for vaccine development. This Special Issue will focus on recent advancements in the design, development, and characterization of glycosylated proteins and nanoparticles as potential vaccines. The Special Issue is open to original research articles and reviews on antigenic/immunogenic oligosaccharides or new glyco-derivatives, as well as pre-clinical and clinical studies on anti-infection or anticancer glyco-(nano)vaccines. Investigations on analytical approaches to support the design and production of glycoconjugates will also be considered.

---

### Guest Editors

Prof. Dr. Marco Terreni

Department of Drug Sciences, School of Pharmacy, University of Pavia,  
Via Taramelli 12, 27100 Pavia, Italy

Dr. Sara Tengattini

Department of Drug Sciences, University of Pavia, Via Taramelli 12,  
27100 Pavia, Italy

---

### Deadline for manuscript submissions

closed (31 August 2025)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/190673](https://mdpi.com/si/190673)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).